Cost-Utility Analysis of Crizotinib as First Line Medication on Late Stage ALK Positive Non-Small Cell Lung Cancer Patients in Taiwan
碩士 === 國立臺灣大學 === 健康政策與管理研究所 === 104 === Purpose: This study aimed to estimate the cost-utility of Crizotinib treatment as first-line medication on late stage ALK positive non-small-cell lung cancer patients compare to current chemotherapy from the payer’s perspective in Taiwan. Methods: A cost-uti...
| Main Authors: | , |
|---|---|
| Other Authors: | |
| Format: | Others |
| Language: | zh-TW |
| Published: |
2016
|
| Online Access: | http://ndltd.ncl.edu.tw/handle/30820932153784582551 |